Volz, N.B.; Hanna, D.L.; Stintzing, S.; Zhang, W.; Yang, D.; Cao, S.; Ning, Y.; Matsusaka, S.; Sunakawa, Y.; Berger, M.D.;
et al. Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients. Cancers 2020, 12, 2947.
https://doi.org/10.3390/cancers12102947
AMA Style
Volz NB, Hanna DL, Stintzing S, Zhang W, Yang D, Cao S, Ning Y, Matsusaka S, Sunakawa Y, Berger MD,
et al. Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients. Cancers. 2020; 12(10):2947.
https://doi.org/10.3390/cancers12102947
Chicago/Turabian Style
Volz, Nico B., Diana L. Hanna, Sebastian Stintzing, Wu Zhang, Dongyun Yang, Shu Cao, Yan Ning, Satoshi Matsusaka, Yu Sunakawa, Martin D. Berger,
and et al. 2020. "Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients" Cancers 12, no. 10: 2947.
https://doi.org/10.3390/cancers12102947
APA Style
Volz, N. B., Hanna, D. L., Stintzing, S., Zhang, W., Yang, D., Cao, S., Ning, Y., Matsusaka, S., Sunakawa, Y., Berger, M. D., Cremolini, C., Loupakis, F., Falcone, A., & Lenz, H.-J.
(2020). Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients. Cancers, 12(10), 2947.
https://doi.org/10.3390/cancers12102947
